Characteristics of patients without germline mutation with tumours showing loss of MLH1 expression and no MLH1 promoter methylation
| Patient | Sex | Age | Site of CRC | Amsterdam | Bethesda | MSI | Protein loss |
| 1 | M | 59 | Descending | No | Yes | Yes | MLH1/PMS2 |
| 2 | F | 72 | Ascending | No | Yes | Yes | MLH1/PMS2 |
| 3 | F | 64 | Caecum | No | No | Yes | MLH1/PMS2 |
| 4 | F | 65 | Ascending | No | No | Yes | MLH1/PMS2 |
| 5 | F | 80 | Sigmoid | No | No | No | MLH1/PMS2 |
| 6 | M | 47 | Caecum | Yes | Yes | Yes | MLH1/PMS2 |
| 7 | F | 52 | Rectum | No | Yes | Yes | MLH1/PMS2 |
| 8 | F | 58 | Hepatic flexure | No | No | No | MLH1/PMS2 |
| 9 | F | 86 | Rectum | No | No | No | MLH1 |
| 10 | F | 70 | Ascending | No | Yes | Yes | MLH1/PMS2 |
| 11 | F | 46 | Caecum | No | Yes | No | MLH1/PMS2 |
| 12 | F | 80 | Caecum | No | No | Yes | MLH1/PMS2 |
| 13 | F | 74 | Hepatic flexure | No | No | No | MLH1/PMS2 |
| 14 | M | 66 | Ascending | No | No | Yes | MLH1/PMS2 |
| 15 | F | 82 | Transverse | No | No | Yes | MLH1/PMS2 |
| 16 | F | 72 | Hepatic flexure | No | No | Yes | MLH1/PMS2 |
| 17 | F | 76 | Ascending | No | Yes | Yes | MLH1/PMS2 |
| 18 | M | 73 | Ascending | No | No | Yes | MLH1/PMS2 |
| 19 | F | 85 | Hepatic flexure | No | No | No | MLH1/PMS2 |
| 20 | M | 47 | Sigmoid | No | Yes | Yes | MLH1/PMS2 |
| 21 | F | 63 | Hepatic flexure | No | No | Yes | MLH1/PMS2 |
| 22 | M | 65 | Rectum | No | No | No | MLH1/PMS2 |
| 23 | M | 79 | Descending | No | No | No | MLH1/PMS2 |
| 24 | M | 52 | Rectum | No | Yes | Yes | MLH1/PMS2 |
| 25 | M | 100 | Transverse | Yes | Yes | Yes | MLH1/PMS2 |
| 26 | M | 76 | Caecum | No | No | Yes | MLH1 |
| 27 | F | 74 | Transverse | No | No | Yes | MLH1/PMS2 |
| 28 | F | 72 | Sigmoid | Yes | Yes | Yes | MLH1/PMS2 |
| 29 | M | 71 | Hepatic flexure | No | No | Yes | MLH1 |
CRC, colorectal cancer; F, female; M, male; MSI, microsatellite instability.